Shares of RedHill Biopharma Ltd (NASDAQ:RDHL) have received a consensus rating of “Buy” from the eight research firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $19.95.
Several equities analysts recently issued reports on the company. Zacks Investment Research raised RedHill Biopharma from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Saturday, May 12th. HC Wainwright set a $36.00 target price on RedHill Biopharma and gave the stock a “buy” rating in a research note on Wednesday, May 9th. ValuEngine lowered RedHill Biopharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 8th. Finally, Nomura assumed coverage on RedHill Biopharma in a research note on Friday, January 26th. They set a “buy” rating and a $18.00 target price on the stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. 683 Capital Management LLC acquired a new position in RedHill Biopharma during the 4th quarter worth about $5,136,000. Creative Planning purchased a new stake in RedHill Biopharma during the 4th quarter worth about $722,000. Virtu Financial LLC purchased a new stake in RedHill Biopharma during the 4th quarter worth about $312,000. Meitav Dash Investments Ltd. purchased a new stake in RedHill Biopharma during the 4th quarter worth about $244,000. Finally, Citadel Advisors LLC purchased a new stake in RedHill Biopharma during the 4th quarter worth about $170,000. 20.03% of the stock is currently owned by hedge funds and other institutional investors.
Shares of RedHill Biopharma stock traded down $0.02 during trading hours on Friday, hitting $7.09. The company’s stock had a trading volume of 7,936 shares, compared to its average volume of 157,054. RedHill Biopharma has a twelve month low of $4.30 and a twelve month high of $11.25. The firm has a market cap of $151.25 million, a PE ratio of -2.73 and a beta of 0.69.
RedHill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.50) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.50). RedHill Biopharma had a negative return on equity of 114.27% and a negative net margin of 726.64%. The business had revenue of $2.45 million for the quarter, compared to analyst estimates of $2.14 million. research analysts expect that RedHill Biopharma will post -1.77 earnings per share for the current year.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions.
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.